Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand1
Patpong Rongkard, Barbara Kronsteiner, Viriya Hantrakun, Kemajittra Jenjaroen, Manutsanun Sumonwiriya, Panjaporn Chaichana, Suchintana Chumseng, Narisara Chantratita, Vanaporn Wuthiekanun, Helen A. Fletcher, Prapit Teparrukkul, Direk Limmathurotsakul, Nicholas P.J. Day, and Susanna J. Dunachie
Author affiliations: University of Oxford, Oxford, UK (P. Rongkard, B. Kronsteiner, N.P.J. Day, S.J. Dunachie); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (P. Rongkard, V. Hantrakun, K. Jenjaroen, M. Sumonwiriya, P. Chaichana, S. Chumseng, N. Chantratita, V. Wuthiekanun, D. Limmathurotsakul, N.P.J. Day, S.J. Dunachie); Mahidol University, Bangkok (N. Chantratita, D. Limmathurotsakul); London School of Hygiene and Tropical Medicine, London, UK (H.A. Fletcher); Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (P. Teparrukkul)
Main Article
Table 1
Proportions of samples from 4 patient and control cohorts used to evaluate immune responses to melioidosis, Thailand*
Cohort |
No. (%) samples by assay
|
IHA or ELISA |
IFN-γ ELISpot |
WBA |
Melioidosis, n = 99 |
73 (74) |
82 (83) |
13 (13) |
Healthy household contacts, n = 96 |
35 (36) |
93 (97) |
8 (8) |
Diabetes control, n = 98 |
54 (55) |
95 (97) |
NA |
Other gram-negative bacterial infections, n = 48 |
10 (20) |
42 (88) |
NA |
Main Article
Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.